A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OReO; OReO/ENGOT Ov-38
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Trial dsign presented at the 42nd European Society for Medical Oncology Congress.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.